If you have ever looked at a cross-pair correlation plot and seen a dip that looks like repulsion, only to learn later that the dip was just an artefact of tissue loss, you know the frustration. That fake signal has misled plenty of good analysis. The recent work using inhomogeneous estimators, random labelling, and brms on a simulated scar plus data from 31 animals after ischemia is a practical step toward separating what is real from what is merely missing. Our take is straightforward: this is the kind of methodological clarity that should become standard, not specialist knowledge.
Too many spatial analyses treat their study area as if it were uniform. When tissue is lost, whether through scarring, ischemia, or dissection, the empty space looks like avoidance to a naive estimator. The inhomogeneous approach described here corrects for that, and the combination with random labelling and Bayesian regression (brms) gives researchers a replicable path. This matters because it shifts the conversation from "is there a pattern?" to "what does the pattern actually mean?" It connects directly to the kind of grounded thinking we saw in Explore how Usul turns complex neural networks into simple math, where abstraction is stripped back to something you can verify. And it echoes the caution in Let AI Polish Your Ideas, Not Dream Them Up: tools that generate patterns are not the same as tools that test them.
The practical consequence for anyone working with spatial point patterns is that the old default, a homogeneous null model, is no longer defensible when your data contain holes. The simulated scar in this work is a clean example, but real tissue loss is rarely that neat. The inhomogeneous estimator does not eliminate the need for domain knowledge; it forces you to specify where the tissue is and where it is not, which is a better problem to have. Researchers who adopt this approach will find themselves asking harder questions about their experimental design, and that is a sign of progress.
What we are watching closely is how this method scales to other types of missing data, not just physical tissue loss but also censored regions, edge effects, or irregular sampling. The 31-animal ischemia dataset is a strong proof of concept, but the real test will come when labs apply the same pipeline to their own heterogeneous samples. One specific detail to watch: whether the random labelling step remains robust when the missing regions are not randomly distributed relative to the points. If it holds, this becomes a transferable tool. If it does not, the next iteration will need to account for non-random missingness directly. Either way, the conversation has moved from "is the repulsion real?" to "how do we measure what we actually have?" That is a better question to be asking.